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Drug-induced liver toxicity dominates the reasons for pharmaceutical product ban, withdrawal or non-
approval since the thalidomide disaster in the late-1950s. Hopes to finally solve the liver toxicity test
dilemma have recently risen to a historic level based on the latest progress in human microfluidic tissue
culture devices. Chip-based human liver equivalents are envisaged to identify liver toxic agents regularly
undiscovered by current test procedures at industrial throughput. In this review, we focus on advanced
microfluidic microscale liver equivalents, appraising them against the level of architectural and,
consequently, functional identity with their human counterpart in vivo. We emphasise the inherent
relationship between human liver architecture and its drug-induced injury. Furthermore, we plot the
current socio-economic drug development environment against the possible value such systems may add.
Finally, we try to sketch a forecast for translational innovations in the field.
Introduction
According to the United Nations, more than 624 pharmaceu-
tical products have been banned, withdrawn, severely
restricted, or not approved by governments since the late-
1950s.1,2 Drug-induced liver injury (DILI) is one of the most
prominent reasons. This underlines the exposure of the
human liver to toxic agents against the background of its
gatekeeping drug metabolism and detoxification duty in man.
Industrially established high throughput hepatocyte test
assays in static 2D or 3D tissue culture are limited to the
assessment of perturbations in pathways of toxicity (PoTs) only
at the molecular, organelle and cellular levels of hepatocytes.
Predictiveness of animal testing suffers from the phylogenetic
distances between animals and humans. New chemical
entities (NCEs) fail (46%) in subsequent clinical studies in
humans due to toxicity.3 The outstanding importance that
liver toxicity has for regulatory bodies is reflected in the
following quote from the US Food and Drug Administration
(FDA): ‘‘The presence of even a single case of severe liver injury
resulting from treatment in the premarketing clinical trials
database is a signal of a high level of hepatotoxic risk.’’4
Therefore, the industry is in dire need of model systems for
drug candidate testing that are of significantly better
predictive value for drug-induced liver injury in humans. A
much better match of in vitro liver models to human in vivo
biology is urgently required to predict the mode-of-action
(MoA) at liver organ level, and to eventually trace the entire
adverse outcome pathway (AOP)5 of an unknown toxic agent
from the molecular initiating event up to the individual
human organism. The National Research Council in the USA
has put forward their Toxicity Testing in the 21st Century
vision,6 which has been backed by all the relevant govern-
mental institutes,7 to transform environmental health protec-
tion.8 The US Environmental Protection Agency’s ToxCast
research programme, with a commitment to transparency and
the public release of all data, was launched in 2007.9 In the EU,
driven by animal protection movement spirit and regulatory
pressure, an impressive number of scientific initiatives in this
regard have been funded over the last decade. These are aimed
at the transition to an AOP-based paradigm for chemical safety
assessment, with a main focus on the integration of existing in
vivo data with in vitro and in silico approaches.10–13 It has been
thoroughly recognised that physiological fluid flow through
the liver tissue is one essential prerequisite on the biological
side of the coin. Miniaturisation for high throughput at a
minimal liver tissue requirement is the other prerequisite on
the economical side of the coin. Micro-electro mechanical
systems (MEMS) – here called chip-based systems – have been
claimed to potentially meet with both of these requirements.
Recent general reviews of ‘‘organ-on-a-chip’’ and ‘‘body-on-a-
chip’’ devices describe the technological improvements in this
emerging field over the last decade.14–17 Furthermore, various
traditional and novel in vitro liver models for toxicity testing,
with a particular focus on cell sources involved in liver
modelling, were reviewed by Soldatow and colleagues.18
Finally, an in-depth description of the potential that micro-
fluidic technologies can add to systematic drug toxicity studies
was written by Sung and Shuler.19 In this review, we stress the
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tight relationship between liver architecture and its biological
function and, consequently, DILI. We critically review existing
chip-based liver equivalents regarding their equivalence to the
human liver lobule, the smallest functional unit of the liver. At
the end, we sketch a forecast for translational innovations in
the field.
Liver architecture and its drug-induced
injury
The unique importance of the liver for organismal home-
ostasis (e.g. plasma protein synthesis, glucose biotransforma-
tion) and blood detoxification (e.g. urea, xenobiotic drug
metabolism) has led to a superior evolutionary optimisation of
the human liver architecture at the scale of its smallest
functional unit – the liver lobule. A precise zonal division of
labour along a stretch (500 mm long) of about 25 hepatocytes
arranged in cords allow the management of blood detoxifica-
tion at a blood contact time of only a few seconds.
Unsurprisingly, such a superoptimised microfacility is espe-
cially vulnerable to inconsistencies, such as toxic effects. This
inherent linkage between lobular architecture and the
mechanism of DILI requires special attention with regard to
the formidable task of providing miniaturised liver equivalents
which respond naturally to any toxic agents. Here, we briefly
introduce human liver architecture and DILI with a special
focus on those elements we believe to be crucial for chip-based
equivalents.
Human liver architecture
The liver is the primary site of biotransformation, degradation
and detoxification of exogenous and endogenous substances
primarily ingested through the gastrointestinal tract. It is built
of 1 to 1.5 million hepatic lobules (classic definition), each of
cylindrical shape approximately 1.1 mm diameter and 1.7 mm
long.20 Blood from the portal tract, containing the ingested
substances, approaches all surfaces of the lobules through a
tiny network of capillaries, which restructure into so-called
sinusoids (diameter 6–10 mm)21–24 for plasma contact with
hepatocytes in the inner part of the lobules (Fig. 1). After
detoxification, blood is collected through a venule in the
centre of the cylinder. Portal blood at the entrance mixes with
arterial oxygen-rich blood at a ratio of 3 : 1, respectively, to
provide oxygen to the liver lobules.25 The oxygen consumption
Fig. 1 Liver zonation at lobule level – architecture defines functionality. Periportal and perivenous zonal specialisation of hepatocyte activity is enabled by a
sophisticated architecture of the liver lobule – the smallest functional unit of the liver. A stable oxygen gradient is ensured by a dynamic arrangement of blood flow
from the outer surface to the centre of the lobule (red arrow), whilst a reverse bile flow takes place in segregated bile canaliculi (green arrow and channels). The space
of Disse, generated by tight interactions between liver cells (brownish) and endothelial sinusoids (blue), accounts for efficient substance uptake. Ito cells (yellow) are
responsible for matrix formation and remodelling in the space of Disse.
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along the approximately 500 mm stretch of blood contact with
liver cell cords creates a functionally important oxygen
gradient (DpO2 30–35 mmHg).
21 It is evident that the oxygen
gradient is a main driver of liver zonation.26–28 Liver zonation
is an evolutionary optimised segregation of the broad liver
functions into spatial, temporarily defined, highly specialized
zones. This enables hepatocytes of their respective zone to
fully concentrate their cellular and molecular capacities onto
the single function to which they are dedicated. The distribu-
tion of key biotransformation pathways along the cords are
highlighted in Fig. 1. This, for example, allows such important
processes as albumin synthesis and glucose release in the
periportal zone to run separately from, for example, glutamine
formation and xenobiotic metabolism in the perivenous
zone.29 As a result of this zonation, DILI events also show a
considerable degree of zonal preference depending on the
properties of the respective toxic or allergic agent. A detailed
listing of substances causing zonal-specific hepatic injury
appears in Gebhardt.27 The centrilobular zone is targeted by
acetaminophen,30 for example.
A single liver lobule contains approximately 105 cells in total
with a yield and volume distribution as shown in Table 1. The
polar hepatocytes are of polygonal shape with approximately
22 mm side lengths arranged in cords. About 37% of the
external membrane of the hepatocytes is sinusoidal surface.20
The absorptive and secretory function of the liver cell is
increased six-fold by numerous microvilli, each 0.5 mm in
length.20,31 These microvilli lie in the space of Disse; some
even protrude through the fenestrae into the sinusoids and,
thereby, have direct contact with the blood.20,32 The apical
surface makes up 15% of the cell’s surface area. Neighbouring
hepatocytes form bile canaliculi (1–2 mm) by an invagination of
their plasma membrane.31,25 A single hepatocyte has contact
with six to ten other hepatocytes. Again, microvilli extend into
bile canaliculi to improve bile secretion. The remaining 50% of
the hepatocyte membrane is made up of the smooth
intercellular fissure, with tight junctions sealing it from the
canaliculi and space of Disse.
The prime area of substance uptake is the space of Disse.
This is a 0.2 to 1.4 mm wide area31,21 which connects the
hepatocyte cords and the liver sinusoidal endothelial cells,
which lack a basement membrane. Plasma approaches the
space of Disse through evenly distributed fenestrae. These
fenestrae have a diameter of 100 to 200 nm, occur at a
frequency of 9–13 per mm2 and occupy 6–8% of the endothelial
surface (see Fig. 1).33 In addition, soluble macromolecules and
colloids of ,0.23 mm can be transported from blood through
endothelial cells by receptor-mediated endocytosis.33,34 The
hepatic stellate cells (about 5% of liver cells) reside in the
space of Disse, are vitamin A-storing pericytes and the main
matrix-producing cell type in the liver. Extracellular matrix in
the space of Disse is mainly based on fibronectin and collagen.
Thick cross-banded collagen type I fibres can be found
throughout the whole space. Furthermore, they play an
important role in regeneration, associated with angiogenesis
and vascular remodelling, differentiation and inflamma-
tion.21,35–38 During liver fibrosis, these cells become activated,
acquiring a myofibroblast-like phenotype and starting to
produce more extracellular matrix. A thorough review on the
origin of these cells, their function in normal liver, and in liver
injury and repair can be found elsewhere.39 Kupffer cells are
another important cell type which preferentially reside in the
sinusoid of the periportal zone and form almost 80% of the
macrophage population. They present antigens and release
numerous signalling molecules, which at peak reactivity can
lead to hepatic injury. They ingest and degrade aged
erythrocytes, bacteria and various endotoxins, and have
endocytotic and cytotoxic activity. This population is respon-
sible for allergic DILI. A prime physiological function of
Kupffer cells is the induction of tolerance to ingested foreign
antigens by immune deviation, active suppression and
induction of T cell apoptosis. Their dysfunction may lead to
toxic autoimmune responses. Finally, it is important to
recognise that hepatocytes in the liver lobule have a natural
turnover of 15 days and are capable of rapidly regenerating
cord structures after damage.
Summarizing, human liver detoxifies ingested substances
within a few seconds along a hepatocyte contact length of 0.5
mm. Plasma contact is mediated by passive filtration and
active transport through sinusoidal endothelial cells. This
amazing metabolic ability is due to the evolutionarily fine-
tuned architecture at liver lobule level. Not much is known
about the fluid dynamics of plasma–hepatocyte contact within
that interval. The nature of the plasma flow in the space of
Disse and the mechanics applied to hepatocytes at these
basolateral surfaces are under dispute. The high degree of
fenestration may result in the significant transmission of fluid
shear stress to hepatocytes. Furthermore, the sinusoids in the
periportal zone are of very small diameter at the size of an
erythrocyte. Blood cell passage through these tight sinusoids
may additionally modulate shear stress. It seems obvious that
any specific DILI occurs against the background of the specific
local microenvironment, cellular responsiveness and tissue
crosstalk in a particular zone of a liver lobule. The emulation
of this local spatiotemporal microenvironment or the entire
dynamic system seem to be crucial for the ability of any in vitro
liver model to predict DILI toxicity.
Drug induced liver injury – what is the problem?
Two types of DILI have been identified over the last 50 years.
Type A, also called intrinsic, is a dose-dependent type of
toxicity with a high incidence and short latency. The majority
of liver injuries of this type become evident throughout
preclinical animal and in vitro toxicity studies. Failure to
identify at the preclinical stage is responsible for compound
Table 1 Yield and volume distribution of cells within the liver lobulea
Number Volume
(% of total) (% of total)
Hepatocytes 60–65 78
Sinusoidal endothelial cells 10–20 2.8
Kupffer cells 8–12 2.1
Ito (stellate cells) 3–8 1.4
Pit cells ,2
a The extra cellular space accounts for 16% of total liver volume (5%
space of Disse, 11% sinusoidal lumina).
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attrition or dose restriction in clinical development. A prime
example is acetaminophen, often used as a reference toxicant
in in vitro studies. Hoehme and colleagues23 substantiated the
crucial importance of hepatocyte–endothelial crosstalk for
repair of Type A DILI in mice, establishing an in silico model
for the repair of drug-induced liver lobule injury. CCl4 causes
hepatocytes close to the central vein to die since only these
cells express CYP2E1, which metabolically activates CCl4 to the
toxic entity. This pattern of toxicity is similar to that caused in
humans by an overdose of acetaminophen. The model has
given unprecedented insights into the dynamics of DILI and
regeneration at single liver lobule level in mice. This model
has been backed by experimental data and it highlights the
exclusive importance of the spatiotemporal interplay of
hepatocytes and sinusoidal endothelial cells for proper
hepatocyte cord repair after significant perivenous hepatocyte
damage in the lobule.
Type B DILI, also called idiosyncratic, is a sporadic dose-
independent type of injury which accounts for the majority of
hepatotoxicity associated with post-approval medication use.
In this stage, it occurs in 1 : 5000 to 1 : 100 000 individuals
exposed. It is also evident in the late stages of candidate
development, where it causes liver failure, often associated
with allergic liver reaction. Each individual case of Type B DILI
has significant regulatory impact. A prime example has been
AstraZeneca’s anticoagulant Exanta (Ximelagatran), which was
rejected for approval by the FDA in 2004 and, finally,
development was discontinued due to idiosyncratic cases of
liver injury.
Numerous efforts have been made in the past to combine
the huge volume of widespread knowledge on human liver
function, injury and toxicity of chemicals and pharmaceuticals
into sound in silico models to understand and predict DILI.
The most advanced publicly available in silico model correlat-
ing current state of knowledge into a toolbox for DILI
prediction, to our knowledge, is the DILIsymTM human model
(http://www.dilisym.com/Products-Services/the-dilisym-model.
html) developed at the Hamner-UNC Institute for Drug Safety
Sciences, founded under the leadership of Paul Watkins, in
North Carolina in 2009. It is designed to be used during drug
development to provide an enhanced understanding of the
DILI hazard posed by individual molecules and to provide
deeper insight into the mechanisms responsible for DILI
responses observed at various stages of the development
process. A middle-out multi-scale representation of human
physiology for assessing potential DILI hazard in patients is
provided. It includes key liver cell populations (e.g. hepato-
cytes, Kupffer cells), intracellular biochemical systems (e.g.
mitochondrial dysfunction) and whole body dynamics (e.g.
drug distribution and metabolism). Through the generation of
SimPopsTM (alternate parameterizations of the model with
distribution constraints), the DILIsymTM model also includes
inter-individual variability. Compound pharmacokinetics (PK)
and pharmacodynamics (PD) information can be integrated to
predict time profiles of liver enzymes (i.e. alanine amino-
transferase, aspartate aminotransferase), other clinical vari-
ables (e.g. bilirubin, prothrombin time) and tissue properties
(e.g. liver mass, glutathione content). Alternate hypotheses
regarding the downstream mechanisms of drug action can be
investigated, including increased reactive oxygen/nitrogen
species, adenosine triphosphate utilization, direct hepatocyte
necrosis, and inhibition of bile acid transporters.
Summarising the complex nature of DILI requires in vitro
prediction models to emulate the full complexity of a liver
lobule as closely as possible. This is a formidable challenge for
chip-based liver equivalents. Consequently, a stepwise pro-
gression of systems, over and above random hepatocyte 3D
cultures, towards lobule equivalents is apparent. Table 2
Table 2 Relationship between levels of architectural complexity and biological function of human liver equivalents. Levels B and C are each built upon the preceding
level
Level of architecture Additional cell types Additional structure/biology Corresponding functions Additional toxicity read-outs
A Cord-like hepatocyte
architecture
None Hepatocyte polarisation Artificial basolateral uptake
of substances
Responsiveness of
polarised hepatocytes
Formation of bile canaliculi Separated release of
metabolites into
apical bile canaliculi
Effect of short-term
separation of bile-secreted
metabolites from
culture medium
Artificial zonation Zone specific
hepatocyte activity
Activity-related
hepatocyte toxicity
B Endothelial sinusoid
architecture
+ Endothelial cells Formation of apical villi and
space of Disse
Physiological basolateral
uptake of substance
Hepatotoxicity at
physiological uptake levels
Fenestrated endothelia Substance filtration/
transport and tissue
conditioning
Hepatocyte regeneration
along the cords and
endothelial cell toxicity
+ Stellate cells Disse space stabilization ECM production Stellate cell toxicity
C Entire liver lobule + Bile channel epithelia,
including oval cells
Bile channels Complete irreversible
segregation of bile from the
medium/serum and
regeneration potential
Depletion of bile
metabolites from the
canaliculi system and
physiological repair response
+ Blood Physiological zonation Physiological separation
of hepatocyte activities
into the three zones
Zone-specific intrinsic DILI
+ Kupffer cells Sinusoidal
dendritic network
Liver-specific immunity Idiosyncratic DILI
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summarises the three architectural levels which would add
important specific toxicity read-outs due to higher function-
ality.
Chip-based liver equivalents for drug testing
in vitro
A lot of progress has been made in optimising static liver
tissue cultures for toxicity testing to a higher level in in vitro
biology at standard multiwell plate formats compliant with
existing liquid handling robotics for high throughput assays.
Here, we briefly report on the latest developments aiming to
become the next gold standard in industry. In such an assay,
liver microtissues of 100–500 mm size are preformed into
spheroids or established in matrices and cultured under static
conditions. Prime examples are the GravityPlusTM and
GravityTRAPTM platforms of InSphero (Zurich, Switzerland)
and the RegeneTOX-3D-liver of RegeneMed (San Diego,
California, USA). Compliance to robotic liquid handling
systems allow for easy daily media exchange and repeated
dose substance exposure over weeks. The liver microtissues
generated are composed of human primary hepatocytes, co-
cultured with non-parenchymal cells, such as endothelial cells
or Kupffer cells. It was shown earlier that such microtissues,
under optimised static culture conditions, exhibit an artifi-
cially optimised microscale architecture that maintains phe-
notypic functions for several weeks. Their utility for toxicity
testing has been demonstrated through the assessment of
gene expression profiles, phase I/II metabolism, canalicular
transport, secretion of liver-specific products, and suscept-
ibility to hepatotoxins.40 Such systems do not provide
mechanical coupling or physiological morphology, but chemi-
cal coupling into oxygen and nutrient gradients has been well
demonstrated. Therefore, they serve as the minimum thresh-
old level each microfluidic chip-based liver equivalent should
outperform to add value to the toxicity screening landscape.
The main features of microfluidic devices – the microscale and
physiological fluidics – should translate into more representa-
tive liver biology at equal or higher throughput. The well-
established fact that non-parenchymal cells are a mandatory
part of liver functionality and, therefore, should be applied in
vitro should be kept in mind.
In the following section, we review the prime microfluidic
systems which aim to emulate liver functionality. We screened
the literature for chip-based systems and separated them into
random hepatocyte 3D cultures and those with higher level
architectures. We categorized the latter according to the levels
(A–C) introduced in Table 2. We tried to ascertain to which
extent they match the corresponding in vivo-like functionality.
The systems are arranged in the order of their respective level
of biological equivalency.
Relevance of cell sources
Standard industrial human in vitro liver toxicity studies at high
throughput are based on well characterized human cell lines,
such as HepG2 and HepaRG.18,41 Due to their tumorous nature
they differ from primary human hepatocytes in various
aspects. Therefore, primary human hepatocytes are thought
of as the gold-standard for in vitro drug metabolism, enzyme
induction and toxicity studies.18 An impressive indicator for
their functional superiority is their performance in bioartificial
liver assist systems (BALS) successfully bridging the gap for
intoxicated liver-failure patients until a transplantation.42,43
Use of primary hepatocytes combined with a change of cell
culture format to 3D and, more importantly, co-cultivation
with non-parenchymal liver cells, such as endothelial cells,
hepatic stellate cells or Kupffer cells, might improve their
cellular and metabolic functions towards in vivo-like
levels.22,18,44,45 Induced stem cell technologies, recently
awarded with the Nobel Prize in Medicine,46–49 might provide
new solutions to the well described but restricted access to
human liver tissue.50,51
Random dynamic monocultures
A number of microfluidic liver culture devices exposing
hepatocytes in random 3D culture at a lower organisational
level have been engineered and will be discussed in this
section.
A co-culture system of carcinoma cell line HepG2 with Caco-
2 and MCF-7 cells was presented by Imura and colleagues
(Fig. 2a).52,53 The system aims to emulate the hepatic
metabolism combined with intestinal absorption for the
assessment of human breast carcinoma cell responsiveness
to four commonly used drugs. It provides a unidirectional flow
in a chip format, the area of a microscope slide, supporting the
constant perfusion of 2 to 9 6 105 HepG2 cells cultured on
microspheres, corresponding to a cell count of two to nine
human liver lobules. Human MCF-7 cell line-based human
breast carcinoma cells were consecutively arranged in a single
microchannel. Drugs are provided through a fluid-tight
monolayer of human Caco-2 cells (intestinal epithelial
tumour) into the culture medium flow of the channel in front
of the liver compartment. The Caco-2 cell layer mimics the
absorptive properties of the human intestine. Exposure was
achieved for two days at a flow rate of 0.4 ml min21, and led to
detectable biological effects on the human breast carcinoma
cells.52 A nutrient gradient might occur in the cylindrical
vertical part of the hepatocyte culture in the channel. Oxygen
should not be limited due to the PDMS nature of the channel.
The hepatocyte arrangement on spheres is artificial.
A system developed for pharmacokinetic and pharmacody-
namic modelling by Shuler’s group54 (Fig. 2b) has been
improved regarding culture format frommonolayer hepatocyte
cultures to 3D hydrogel supported cultures.55 It combines
cultures of human hepatoma cells HepG2/C3A with colon
cancer cells and myeloblasts in separate cell culture chambers.
The system, at its selected scale, provides in vivo-like tissue
mass ratios inside the culture compartments, a culture
medium inflow split that is equivalent to the respective blood
flow split in humans, and relevant residence times in the
tissue compartments. Furthermore, the microfluidic chip
design is claimed to support physiological shear stress and
liquid-to-cell ratios comparable to those of the respective
organs, and it can be operated over periods of up to four days.
In order to ensure proper residence times and volumetric
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velocities, the flow rate in that system has been adjusted to a
velocity of 168 mm s21 in the liver compartment, which is close
to the in vivo situation, while cell density and liver compart-
ment architecture are not. The number of liver cells is 105,
corresponding to one human liver lobule. Apart from the
missing architecture, this is one of the few systems which
Fig. 2 Metabolically active liver equivalents at elementary architectural level. (a) Schematics of a multi-tissue device exposing hepatocytes on microspheres in a packet
cylinder to substances delivered through an intestine barrier. (Reproduced from ref. 52. Copyright 2010 American Chemical Society). A 3D matrigel-based hepatocyte
culture, schematically shown in (b), was integrated into mCCA to increase the level of hepatocyte arrangement. (Reproduced from ref. 55 with permission). (c)
Schematic layout and perspective view photograph of a chip-based liver equivalent composed of consecutively arranged microchannel geometries with a total
surface of 2 cm2 supporting hepatocyte attachment (0.1–0.5 6 106 cell seeding). (Reproduced from ref. 57 with permission of Elsevier). (d) Schematic of a system
arranging hepatocytes in a 1 cm cord fluidicly interconnected with other relevant tissues. Shear stress shielding is provided by micropillars as illustrated. (Reproduced
from ref. 63 with permission). (e) The schematic layout of another system arranging hepatocytes in cord-like structures, but with additional microstructures at the
channel bottom allowing traverse fluid flow. (Reproduced from ref. 66 with permission). (f) Perspective view photograph and schematic of a sieve-pocket-based
hepatocyte culture space supporting a cord-like dense package of 250 hepatocytes shielded by a microchannel barrier. (Reproduced from ref. 68. Copyright 2007
John Wiley and Sons). Systems providing a multi-tissue approach are circled in grey.
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combines several culture compartments into a combined
recirculation supporting molecular crosstalk. To the best of
our knowledge, it represents the first and, until recently, the
only dynamic microscale system supporting a physiologically
based pharmacokinetic, quantitative structure–activity rela-
tionship (QSAR) and quantitative in vitro to in vivo extrapola-
tion modelling.56
A system proving acetaminophen sensitivity of 3D clusters of
HepG2/C3A cells with four-day activity was developed by
Baudoin and colleagues (Fig. 2c).57 The biochip environment
contributed to the upregulation of principal enzymes involved
in phase I and II metabolism and phase III transporters.58
Data suggest superior metabolic activity of the HepG2/C3A
cells in comparison to their culture in Petri dishes. A biochip
with a culture space of 40 ml contains 1 to 56 105 hepatocytes,
which corresponds to approximately 1 to 5 liver lobules in
humans. The system aims for an even and continuous
distribution of nutrients and oxygen. Gradients and, conse-
quently, liver tissue zonation was not targeted.
Other systems with lower organizational degrees of hepato-
cyte cultures not focusing on architectural resemblance are
described in the literature, but are not reviewed further
here.59–61
Cord-like liver equivalents
Since their inception, numerous microfluidic devices have
been established for the arrangement and maintenance of
hepatocytes in cord-like structures with the potential to ensure
physiological hepatocyte polarisation, release of bile into
canaliculi and artificial functional zonation. A very interesting
system on this level of biology is that of Zhang and colleagues.
They developed a microfluidic channel-based system (1 cm
long, 200 mm wide, 100 mm high) with an integrated array of
micropillars Fig. 2d).62 About 4 6 103 cells per channel were
applied, which corresponds to approximately 0.05 liver lobule.
Cells were perfusion-seeded into these structures, achieving a
high 3D cell–cell interaction. A thin layer of matrix was layered
over the 3D cells by a polyelectrolyte complex coacervation
process.63 The cells preserved their 3D cyto-architecture and
cell-specific functions for the whole cultivation period of up to
one week. The use of intercellular polymeric linkers, such as
polyethyleneimine-hydrazide, which stabilise the multicellular
aggregates, facilitate the establishment of a more natural
extracellular matrix environment.64 This intercellular linker
gradually disappears from the cell surface within two days,
allowing the cells to secrete their own matrix. This may
promote more in vivo-like cellular phenotypes when compared
to microfluidic systems incorporating no or exogenous
matrices. The integration of gelatin microspheres which
released TGF-b1 in a controlled way supported hepatocyte
function inside these structures.65 An increased albumin
production and higher phase I and II enzymatic activities,
which improved the sensitivity of the hepatocytes to acetami-
nophen-mediated hepatotoxicity, was shown. In addition to
cord-like hepatocyte arrangement, this system allows for the
combination of liver cells with other cell types within a
common media circulation. It is not obvious if specific
zonation characteristics can be stably achieved within the
system.63
The formation of 3D tissue-like structures composed of
polarised cells which form extended bile canalicular structures
was presented by Goral and colleagues (Fig. 2e).66 Cells were
seeded in a microfluidic device similar to the one
described.64,62 A series of retention pillars formed a micro-
channel centred between two side-channels. However, unlike
other perfusion-based microdevices, the bottom of the cell
culture chamber was patterned with microstructures, which
provided an additional control of hepatocyte polarity.66 In
contrast to Toh et al., the channel is 100 mm wide and hosts
104 cells, corresponding to 0.1 human liver lobule. Cell culture
media could not only be perfused through the cell compart-
ment from the side-channels, but also via these patterned
microstructures on the bottom, minimising cell spreading and
cell–surface interaction. After two weeks of perfusion culture,
the cells remained viable and had formed a cord-like structure.
An extended bile canalicular structure and the formation of
gap junctions between the 3D structured cells could be
shown.66 A clear segregation of bile within the cord structures
could be achieved. The patterned microstructures at the
bottom are the first step toward technical approaches allowing
the separation of bile.
Another cord-like arrangement of hepatocytes could be
achieved in a system by Lee and colleagues, additionally
aiming to emulate the functions of the space of Disse through
a microporous microfluidic barrier (Fig. 2f).67 Cells were
cultured inside a sieved-pocket cell culture area (150 mm wide,
440 mm long) corresponding to 250 densely packed hepato-
cytes – a very small fraction of a human lobule – without
nutrient limitation for over one week. Nutrient depletion was
avoided by a continuous maintained flow of medium around
the pocket, which diffused across the porous barrier to the
cells. It was hypothesized that the flow dynamics of the media
may provide necessary cues for hepatocyte differentiation and
function.67 The hepatotoxic effect of diclofenac on human
primary hepatocytes cultured in this device could be
mimicked.68 Diclofenac is a model compound for metabo-
lism-mediated hepatotoxicity, as it exhibits its toxic effect only
after prolonged exposure (24 h) to metabolically competent
cells. Furthermore, the high cell density allowed for an
enhanced cell–cell contact with tight junctions and desmo-
somes. Multi-cellular spheroids were formed that preserved
the viability and metabolic activity of the cells over many
weeks. This system seems to provide an even distribution of
nutrients and oxygen without dynamic oxygen and nutrient
gradients important for zonation in vivo. Therefore, it might
reflect a certain local microenvironment within a lobule. The
obvious difficulty in determining cell damage exactly in such
small sieve-pockets of 250 cells has been addressed by
Meissner and colleagues.69 They provided a solution for an
integrated label-free impedimetric toxicity screening capable
of detecting cellular damage in microscale sieve-pockets.
Endothelial sinusoid model and hepatic lobule ‘‘equivalent’’
The systems mentioned above succeeded in arranging
hepatocytes into an artificial but cord-like assembly, restoring
hepatocyte polarity and supporting sporadic bile segregation.
Co-culture of hepatocytes with non-parenchymal cells in a
spatially arranged 3D environment under constant perfusion
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might lead to the formation of basolateral villi and space of
Disse on the background of fenestrated endothelia – a next
level of architectural resemblance to the in vivo situation. A
very interesting approach to modelling sinusoid like structures
in a microfluidic system has been developed by Domansky and
colleagues (Fig. 3a).70 An array of multiple bioreactors was
build into a multiwell plate comprising 12 autonomous
microfluidic systems, each being perfused by an integrated
pneumatic micropump circulating a total volume of 3 ml. Each
tissue culture scaffold contains 769 multichannels (0.24 mm
deep, 0.34 mm diameter) and was seeded with 106 rat
hepatocytes and endothelial cells at a 1 : 1 ratio. With regard
to hepatocyte numbers, this corresponds to approximately 10
human liver lobules. A continuous adjustable oxygen gradient
could be established over long operating times. The scaffold
supports near physiological tissue densities and the functional
zonation of hepatocytes can be stipulated. The large channels
of the scaffold support self-assembly of the two cell types in
dynamic conditions. Liver sinusoid endothelial cells, known to
lose their differentiated phenotype in vitro, maintained the
expression of the functional marker SE-1 throughout the
culture.70 The important features of adjustable flow rates on
the basis of an oxygen consumption model, long-term steady
gradient maintenance and the ability for co-culture of
hepatocytes with different types of non-parenchymal cells
made the system an interesting alternative for toxicity testing.
The highest level of architecture – the entire liver lobule –
has not yet been reached, but a chip-based microfluidic
approach to contain a major part of a liver lobule has been
made by van Midwoud and colleagues (Fig. 3b), who cultivated
3 mg of liver slice tissue. The precision cut liver slice (100 mm
thick, 4 mm diameter) was perfused by a 10 ml min21 media
flow in an incubator chamber with constant pH and dissolved
oxygen.71 In a human setting, the tissue used here would
correspond to approximately two liver lobules (around 26 105
liver cells). Biotransformation activity was shown to be equal
in control slices in static culture over three hours. The system
does not demonstrate any advantage with regard to metabolic
Fig. 3 Systems emulating higher level liver lobule architecture. (a) Perspective view photograph of a parallel multiplate bioreactor hosting 12 liver equivalents and the
schematic cross-section of a single liver equivalent culture compartment operated by a peristaltic micropump. A sinusoidal architecture was rebuilt by co-culturing
hepatocytes and endothelial cells within microchannels (240 mm long) of a scaffold. Hepatocyte villi and endothelial fenestrae at the hepatocyte endothelial interface,
observed in electron micrograph, substantiated sinusoidal architecture. (Reprinted from ref. 70 with permission). (b) Perspective view photograph of a microfluidic
biochip hosting 4 liver equivalents and schematic layout of a single perfusion culture for a 100 mm 6 4 mm precision cut liver slice initially comprising the
physiological architecture of a part of a liver lobule, although heavily damaged. (Reproduced from ref. 71. Copyright 2010 John Wiley and Sons).
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functionality over the three-hour measurement time. The
authors highlight the advantage of continuous media perfu-
sion at low tissue-to-fluid volume ratios in contrast to steady
metabolite accumulation in static culture. Unfortunately, data
on the culture performance over longer times than 72 h are not
presented.72 Although the lobules’ architecture within the
tissue was preserved, the artificial media perfusion is not able
to eventually provide a dynamic oxygen gradient and, conse-
quently, spatiotemporal zonation. Finally, the system does not
assist the segregation of bile and media flow. The only other
example in the literature of maintaining liver tissue slices in a
microfluidic arrangement has been published by Hattersley
and colleagues.73 The authors succeeded in maintaining viable
liver slices 71 h with albumin secretion varying in a cyclic
manner peaking every 24 h and urea remaining relatively
stable.
To the best of our knowledge, no other microfluidic devices
have been described which apply complex liver lobule tissue
biopsies or create this complexity in the systems and,
furthermore, show this degree of tissue viability. Neither of
these hepatic lobule ‘‘equivalents’’ provides a physiological
connection of an entire liver lobule to a surrogate of a blood
microcirculation and bile removal. Therefore, the achievement
of improved functionality and toxicity read-outs highlighted in
Table 2 are not possible.
Complex organotypicalness versus cost-efficient throughput
We have plotted a representative array of existing chip-based
liver equivalents for drug toxicity testing against the level of
human biology they try to emulate (Table 2).
None of the systems developed to date ultimately mirrors
the architecture of a human liver lobule at full-scale complex-
ity. However significant improvements towards higher levels of
functionality and, consequently, toxicity read-outs have been
made with cord-like architectures. Chip-based liver tissue slice
culture and a sinusoid liver model co-culturing hepatocytes
and endothelial cells under fluid flow shear stress are the most
advanced systems with regard to the organisational complexity
of cultured tissues. The former is at a very early research level
with irrelevantly short operational time. The latter has been
transferred from research74–76 into a LiverChip perfusion plate
(Zyoxel, Cambridge, UK). This commercial system is well
characterised with regard to metabolism and function related
to toxicity. It is designed to support toxicity evaluation over at
least three weeks. We identified a second commercially
available microfluidic liver equivalent system – the Pearl
microfluidic perfusion array (CellAsic, Hayward, California,
USA). It works with passive unidirectional perfusion (100 ml
day21) with 32 samples (25 000 cells each) on a 96-well plate
format over 30 days with hepatocytes being shielded from
shear stress by an endothelial sieve surrogate. Human
hepatocytes are concentrated into high density cords and
provided with oxygen through air diffusion channels. Porous
‘‘sinusoid’’ channels run in between cell regions comparable
to those reported by Lee and colleagues described above.
Finally, HmRELflowTM, a system based on the mCCA of Shuler
and colleagues, described above, seemed to be commercially
available (HmRel corporation, Beverly Hills, California USA). To
the best of our knowledge, these are the only three
microfluidic devices on the market consisting of human liver
equivalents for toxicity testing; their robust validation and
comparison with static liver microtissue culture systems, such
as GravityPlusTM and RegeneTOX-3D-liver described above,
have not yet been completed by the pharmaceutical industry. It
is worth noting that the level of automated parameter control,
such as in-process controls of pH and pO2, of the chip-based
liver equivalents reviewed here do not compare with the
advanced macroscale bioartificial liver-assist systems used at
the patient’s bedside, and the corresponding hollow fibre-
based research liver bioreactor system of Zeilinger and
colleagues.77,78
With regard to the commercial element, throughput and
costs, the features listed in Table 3 highlight two obvious facts:
(i) The liver equivalent number operated by the devices
reported is far from being compliant with high throughput
requirements, and (ii) ensuring circulating fluid flow in liver
equivalents requires pump systems with control units
attached. Any such addition of technical equipment to operate
the chip-based liver equivalents, limits their throughput
capacity at increasing costs per single test point.
Nowadays, drug candidates undergo a finely tuned multi-
step characterisation and selection process from discovery to
market approval. A rapidly decreasing gradient of test
throughput applies to that process to select a single successful
candidate out of about 10 000 initial compounds.
Simultaneously, costs associated with the development of a
single entity to market approval, rapidly increase at late stage
development associated with clinical trial expenditures. The
Table 3 Key parameters of reviewed chip-based liver equivalents
Biological complexity
Cultures
per device
Cells per
culture
Density
(cells cm23)a Chip volume Co-culture Multi-tissue
Circulating
medium Reference
Hepatic lobule equivalent 4 2 6 105 3 6 108 0.6 ml h21 Yes No No 71
Endothelial sinusoid model 12 106 0.5 6 108 15 ml h21 Yes No Yes 70
Cord-like liver equivalents 1 250 2 6 108 0.6–1.2 ml h21 No No No 68
Cord-like liver equivalents 1 104 109 5 ml h21 No No No 66
Cord-like liver equivalents 1 y4 6 103 1.8 6 107 200 ml h21 No Yes No 63
Random dynamic monocultures 1 0.1–0.5 6 106 3 6 107 up to 1.5 ml h21 No No Yes 57
Random dynamic monocultures 6 105 107 160 mm s21 No Yes Yes 55
Random dynamic monocultures 1 2–9 6 105 3.75 6 107 24 ml h21 No Yes No 52
a In vivo cell densities in liver lobules corresponds to 3 6 108 cells cm23.
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major high throughput burden is at the stage of early
discovery, it goes down to several hundred test animals per
compound in the preclinical toxicity stage and rarely more
than 50–60 human test volunteers in the clinical safety
assessment stage (Phase 1). Clinical efficacy evaluation
(Phases 2 and 3) usually requires several thousand patients.
Intrinsic DILIs cause attrition rates in early clinical develop-
ment, whilst idiosyncratic DILI appears in late clinical trials as
the cohorts increase in size. There is no further economical
playground to increase preclinical costs unless a significant
move toward human biology and predictiveness is made. All
systems reviewed here are at an early stage and require
validation prior to use in routine toxicity screening. Advanced
high throughput compliant static 3D liver cultures are the
benchmark chip-based human liver models have to outper-
form at equal or lower price if the added value is incremental.
Only translational solutions to the toxicity dilemma legitimise
higher level expenditures.
Many hurdles
Screening the current picture, we have identified that chip-
based liver equivalents for toxicity testing are at a very early
research stage of their development. A broad variety of system
designs operated with very different process parameters exist.
Therefore, microfluidic platforms aiming to add value to liver
toxicity testing of pharmaceutical entities still face major
challenges. Here, we discuss possible approaches to step into
the future.
Status quo and fit with modern toxicity requirements
Nowadays, the pharmaceutical and consumer industries face a
paradigm shift in their safety assessment strategies. The dire
need to quickly and efficiently select potential hits for toxicity
is a potent driver for the implementation of in vitro assays
emulating a higher degree of human biology. This is backed by
the US FDA, quoting FDA commissioner Margaret A.
Hamburg: ‘‘We must bring 21st century approaches to 21st
century products and problems. Toxicology is a prime
example. We need better predictive models to identify
concerns earlier in the product development process to reduce
time and costs.’’79 It implies a transition to an AOP-based
paradigm for safety assessment in toxicology. This paradigm,
schematically outlined in Fig. 4, implies that an initiating
molecular event, caused by a toxic agent leads to a series of
consequences on at least three levels of biological complexity
to finally end up with the undesired adverse outcome.
The agent-specific adverse outcome pathway includes all
three levels:
i. The molecular interaction with a receptor, DNA or protein
inducing, e.g. gene activation, altered signalling or protein
production or depletion at a cellular level, representing the
pathway of toxicity (PoT) of the toxic agent;
ii. alteration of physiological function, disrupted local
homeostasis and altered local tissue development, e.g. liver
fibrosis at tissue and organ level, i and ii together representing
the mode of action (MoA) of the toxic agent;
iii. and finally, multi-organ failure and lethality or impaired
development and reproduction, i, ii and iii together represent-
ing the adverse outcome pathway (AOP) of the respective toxic
agent.
Fig. 4 The adverse outcome pathway paradigm in safety assessment. According to the AOP paradigm, the value of in vitro methods to predict DILI increases with the
degree of emulation of the liver (MoA level) or the human body as a whole (AOP level). Chip-based liver equivalents, reviewed here, have made the first early progress
into liver lobule modelling. With the translational improvement of MEMS technologies, full-scale emulation of human liver lobules and, finally, ‘‘Human-on-a-chip’’
devices may raise preclinical prediction of DILI to a historical score.
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Conventional static liver cultures and random dynamic chip-
based hepatocyte cultures, nowadays, support the identifica-
tion of pathways of toxicity restricted to acute toxicity due to
limited substance exposure times and lack of architectural
complexity in vitro. With the growing complexity of liver
equivalents in vitro and rising robustness of tissue main-
tenance over long periods, MoA analysis may come within
reach both for acute and chronic toxicity at repeated doses.
The endothelial sinusoid and liver lobule emulating micro-
fluidic devices reviewed here are the very first step in this
direction. Chip-based entire liver lobule equivalents bear the
potential to fully emulate DILI at the single organ level in vitro
in the future. Finally, none of the three architectural levels for
chip-based liver equivalents, summarised in Table 2, would be
able to emulate the AOP of DILI in other organs within an
entire organism.
Prospective improvements of existing chip-based liver
equivalents
We have outlined three architectural levels for human chip-
based liver equivalents which each consequently add a critical
functional feature of human liver and might significantly
improve the predictiveness of toxicity testing in comparison to
random static and dynamic 3D hepatocyte culture. The
following improvements of existing systems might optimise
their performance.
Level A – cord-like hepatocyte architecture: chip-based
systems of this category should be optimised towards the
accurate establishment of an artificial zonation along the
cords. Therefore, the measurement of the local oxygen
gradient and monitoring of single hepatocyte viability, for
example, by live tissue imaging techniques, would be
advantageous. Investigation into the ratio of basolateral
(absorption) versus apical (bile release) surfaces within the
cords might allow comparison with the in vivo situation in
man.
Level B – endothelial sinusoid architecture: in addition to
the optimisation suggested for level A liver equivalents, we
propose the integration of stellate cells at physiological ratios
into endothelial sinusoids in vitro. Investigation into spatially
coordinated proliferation of hepatocytes along the sinusoids
in response to toxic cell losses would prove the added value of
such chip-based liver equivalents for repeated dose toxicity
evaluation. Moreover, it would be interesting to use such
systems in order to discover the biological cues inducing villi
formation on hepatocytes and fenester formation on endothe-
lial cells in human liver.
Level C – entire liver lobule: adding to the aforementioned
improvements of level A and B, physiological lobule-like
zonation of primary hepatocyte cords induced by blood
perfusion and segregation of bile from canaliculi into separate
channels would be the next breakthrough at this level of
human liver equivalents. The first aims for natural zonal
hepatocyte specialisation allowing differentiating individual
PoTs of a toxic agent, e.g. reactive metabolite toxicity and
mitochondrial impairment at physiological levels of hepato-
cyte activity. The second would foster the identification of toxic
agents, inducing intrahepatic choleostasis modulating bile
transport systems. The inclusion of an immune system –
Kupffer cells – would be another important improvement
which would aim for the detection of allergic idiosyncratic
DILIs. Finally, the construction of biological bile channel
covered by epithelial cells, including oval cells, would add
important liver repair functionality crucial to predictive
toxicity testing.
Furthermore, the extension of the multi-tissue systems
reported here at level A in the direction of systems
physiologically arranging an intestine and a kidney equivalent
with a liver equivalent on a chip may enable a new application
for multi-tissue liver equivalents – the generation of ADME
data and PK/PD analysis within one experimental setting.
We recommend the generation of a biological baseline for
any chip-based liver equivalent, leading, in a first step, to the
eventual transfer of a chip-based liver equivalent into
industrial use. It is necessary, therefore, to determine the
architectural and functional correlation of the chip-based liver
equivalent with the in vivo liver based on histology, analysis of
gene expression, protein levels, such as albumin secretion,
CYP450 (selected protein activities – CYP1A, CYP2C, CYP3A),
ATP, GSH, LDH, AST, ALT, and metabolite analysis. We further
recommend the generation of an extensive time course of both
early and late time points and to compare it with data of
standard or advanced static hepatocyte cultures.
In a second step, hepatotoxicants should be assessed by the
chip-based liver equivalents to prove that additional MoA data
beyond PoTs can be derived at the different levels in contrast
to the static and dynamic random hepatocyte models. We
would advise the use of early and late time points and, if
possible, pharmacologically relevant doses. The same read-
outs as those set out in step one could be applied. Toxic agents
might, for example, include acetaminophen, tetracycline
statins or ketoprofen. The application of reversed dosimetrics
with QSAR-estimated partitioning coefficients and metabolism
parameters80,81 will allow human-relevant data to be derived
from these assessments.
In addition to the improvements in the three levels of
biology on a chip, actuators and sensors operating and
controlling the chip-based liver equivalents should be
improved for repeated dose long-term toxicity testing. In-
process monitoring and control for the pO2 gradient along the
cords and pH is mandatory for robust toxicity evaluation. It is
an important part of any of these developments to interact
with available information tools such as the DILIsym in silico
platform, extracting existing knowledge and feeding its own
data.
We believe that industrially validated test assay platforms
for short-term exposure safety assessment might evolve from
any of the ongoing chip-based liver equivalent developments
at any of the three levels. This will identify toxic agents earlier
in discovery, shortening development timelines and eventually
reducing acute systemic toxicity testing in animals.
Optimisation toward standardised cost-effective automated
handling should be a prime focus in order to meet high
industrial throughput requirements at competitive costs.
‘‘Humans-on-a-chip’’ to evaluate AOPs – the ultimate level?
Even an entire chip-based liver lobule equivalent (Table 2 level
C) differs from human biology in a pivotal aspect: The inability
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to emulate the AOP of DILI in other organs within an entire
organism. Therefore, it will be necessary to climb to the next
level of systemic biology – long-term homeostasis of primary
organoids at a miniaturised organismal level in vitro. Given an
ethically acceptable supply of the necessary human tissues, by
carefully weighing ethical issues against medical needs,
‘‘human-on-a-chip’’ systems that provide unlimited home-
ostasis and organoid repair capability on the basis of
biological vascularisation, physiological blood perfusion and
the maintenance of organ-specific stem cell niches, could be a
translational approach, which we have laid out elsewhere.17 In
brief, human endothelial cell-based blood vasculature should,
therefore, form and interconnect several microvascular beds
into a common blood circulation. Each of the microvascular
beds needs to be integrated into an organ-specific stromal
tissue bed, which provides the respective extracellular matrix-
based microarchitecture for proper organoid assembly.
Orchestrated organ-specific groups of fully functional orga-
noids should maintain their specific functions in concert. The
concept is based on the fact that almost all human organs are
assembled from multiple, identical and functionally self-
reliant structural units, e.g. the liver lobule, which perform
the most prominent functions of the particular organ. The
multiplication of these structures, which have been named
organoids, within a given organ is nature’s risk management
tool to prevent a total loss of functionality during partial organ
damage. With regard to evolution, this concept has allowed
organ size and shape to be easily adjusted to the needs of a
given species – for example, the liver in mice and men – while
following nearly the same arrangement to build up single
functional organoids. It is important that these organoids are
of very small dimensions, from several cell layers up to a few
millimetres. The reactivity of organoids to drugs and biologics
is supposed to be representative of the whole organ because of
their distinguished functionality and a high degree of self-
reliance within the respective organ. Therefore, a prime
approach to fully emulate human organs at a minimum scale
of at least a single organoid per organ (less than 2 ml) might be
the development of vascularised blood-perfused chips sup-
porting an organoid on-chip assembly within the right
microenvironment. Fig. 5 shows an example of this ‘‘human-
on-a-chip’’ concept developed to fit the multi-organ-chip
format the area of a standard microscope slide, developed in
our labs.17 At this chip scale, we are aiming to operate a
‘‘human-on-a-chip’’ 100 000-fold smaller than its in vivo
counterpart. Therefore, the liver equivalent is designed to
host ten human liver lobules. All the other organ compart-
ments are designed to hold a number of their organoids that is
proportional to the ten liver lobules.
The biological level proposed here is a desperate challenge.
It demands, among other things, the provision of actuators
and sensors for the ‘‘human-on-a-chip’’ platforms that match
the functions of their in vivo counterparts. Actuators should
couple a broad range of mechanical stresses differentially into
relevant organs, at natural degrees. Sensors with exceptionally
high sensitivity should be developed to detect the main
parameters of human organismal homeostasis, such as: organ
viability, tissue temperature, pH, daily fluid balance, intraca-
pillary pressure, blood flow volume, oxygen and nutrient
consumption, fluid adsorption and intestinal juice secretion,
albumin and bile synthesis, urea excretion, ion balances,
osmolarity, and electrical coupling in the minute sample
volumes derived from such a miniaturised microfluidic device.
Miniature organ sizes and contact-free access to the transpar-
ent bottom of the chips might allow the use of strong in-
process research tools, such as, two-photon microscopy for
tissue imaging, fluorescence ratio imaging for local interstitial
pH measurement,82 phosphorescence quenching microscopy
for interstitial pO2, or infrared spectroscopy to detect
physiological stresses.83 Systems biology approaches for the
identification of physiological performance, or adverse out-
come pathways at stress overloads, might be applied on
samples daily.84 A few years ago, such a target seemed to be
pure science fiction, but the unprecedented joint development
programme between the NIH, DARPA and the FDA (http://
www.ncats.nih.gov/research/reengineering/tissue-chip/tissue-
chip.html), initiated in 2012, to develop ‘‘human-on-a-chip’’
systems combining ten human systems/organs on a single
chip is a unique hallmark, indicating the translational impact
of such concepts on the drug development pipeline. The
programme has identified leading research groups that are
focusing on chip-based disease model development within the
USA. This is an attractive opportunity to create new research
alliances among all the partners within the field to convert this
vision into a reality. Such a significant move towards
individualised ‘‘humans-on-a-chip’’ justifies substantial devel-
opment and test costs, as it may be rewarded by the ultimate
decrease of attrition rates in clinical trials. The forecasted
complexity of such systems at large throughput might
potentially offer a platform to even identify idiosyncratic
DILI prior to human trials. Finally, it remains wishful thinking
to expect such a ‘‘homunculus’’ (small man) on-a-chip to
develop, for example, consciousness. One must always keep in
mind that the term ‘‘human’’ in ‘‘human-on-a-chip’’ has the
meaning of an artificial copy, effigy or image. The uniqueness
of a human being is inviolable.
Concluding remarks
The development of chip-based liver equivalents for toxicity
testing is at a very early research stage of development. None of
the currently existing systems reviewed here fully matches the
architectural complexity of a human liver lobule, with
precision cut tissue slices being the closest. Only a few chip-
based equivalents, to a certain degree, emulate lower level
complexities, such as hepatocyte cords and sinusoidal
architecture. It is important to note that at least two
microfluidic liver equivalents have already made it into
commercialisation. Their advantages in comparison to
advanced static 3D liver test systems have yet to be demon-
strated by the ongoing feasibility studies in pharmaceutical
companies. The existing microfluidic liver equivalent plat-
forms represent a perfect basis for further improvement into
chip-based liver equivalents providing stable controllable
zonation of hepatocyte cords and segregation of bile.
Furthermore, the combination of the liver equivalents with
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intestine and kidney equivalents may result in chip-based
systems for ADME-Tox testing. Finally, to fully elaborate on the
unique features of MEMS technologies, a forecast towards
‘‘Humans-on-a-chip’’ to predict AOPs for DILI at the level of
the individual organism has been sketched.
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